Aug 21, 2018
MediSieve Announced as Finalist in Medtech Insight Awards 2018
MediSieve has been announced as a finalist in the inaugural Medtech Insight Awards 2018, in the category of Innovative Team of the Year.
LONDON – August 21, 2018 – The medical device company has made waves with their magnetic blood filtration technology, which utilises a cutting-edge method to treat blood-borne diseases such as malaria, sepsis and leukaemia.
It’s clear to see why the medical device company has been shortlisted. Their pioneering technology involves targeting specific components that cause the diseases and removing them from the patient’s bloodstream, providing clinicians with a tool to target and remove infected cells, pathogens, toxins, cytokines and others.
“This has the potential to revolutionise the treatment of a huge variety of blood-borne diseases,” said Dr George Frodsham, founder and CEO of MediSieve. “Our development of the technology focused on a rapid, highly efficient, biocompatible magnetic filter that can safely capture magnetic components from blood flowing through an extra-corporeal loop.”
The company’s success is also down to its innovative team. “It’s an honour to be shortlisted alongside some of the world’s most innovative companies,” said Dr. Frodsham. “And it’s a great platform to raise awareness of the benefits and developments of MediSieve. In the past year-and-a-half, we have solved some big technical challenges, from getting the filter through pre-clinical testing, to generating enough data to win a grant from the NIHR to perform first-in-man clinical trials, to securing £1.75M of funding from investors! This was a feat considering we were only a team of four with very limited resources.”
The Medtech Insight Awards 2018 is dedicated to the work and excellence of companies, teams and individuals in the medtech industry who also are spearheading positive changes. It serves to laud the efforts of those who help to make human lives better through their passion and commitment, of those who push to cure, inform and minimise treatment burden.
This year’s shortlist serves to highlight the wealth of hard work, innovation as well as dedication in the industries of medical device and diagnostics. The categories celebrate various achievements, such as technological innovations, personal accomplishments by both teams and individuals and emerging markets. Its panel comprises of independent experts who work in various areas in the sector and who have established respect in their fields.
The Awards are organised in partnership with the MedTech Conference in Philadelphia, and will be held on the eve of the conference, on Sunday, September 23rd, in the Kimpton Hotel Monaco. Winners will be announced at the awards ceremony and dinner.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: